Merck Long Term Debt 1986-2025 | MRK

Merck long term debt from 1986 to 2025. Long term debt can be defined as the sum of all long term debt fields.
  • Merck long term debt for the quarter ending June 30, 2025 was $33.968B, a 2.16% decline year-over-year.
  • Merck long term debt for 2024 was $34.462B, a 2.31% increase from 2023.
  • Merck long term debt for 2023 was $33.683B, a 17.18% increase from 2022.
  • Merck long term debt for 2022 was $28.745B, a 6.34% decline from 2021.
Merck Annual Long Term Debt
(Millions of US $)
2024 $34,462
2023 $33,683
2022 $28,745
2021 $30,690
2020 $25,360
2019 $22,736
2018 $19,806
2017 $21,353
2016 $24,274
2015 $23,829
2014 $18,699
2013 $20,539
2012 $16,254
2011 $15,525
2010 $15,482
2009 $16,095
2008 $3,943
2007 $3,916
2006 $5,551
2005 $5,126
2004 $4,692
2003 $5,096
2002 $4,879
2001 $4,799
2000 $3,601
1999 $3,144
1998 $3,221
1997 $1,347
1996 $1,156
1995 $1,373
1994 $1,146
1993 $1,121
1992 $496
1991 $494
1990 $124
1989 $118
1988 $143
1987 $167
1986 $168
1985 $171
Merck Quarterly Long Term Debt
(Millions of US $)
2025-06-30 $33,968
2025-03-31 $33,484
2024-12-31 $34,462
2024-09-30 $34,982
2024-06-30 $34,717
2024-03-31 $31,142
2023-12-31 $33,683
2023-09-30 $33,972
2023-06-30 $34,072
2023-03-31 $28,074
2022-12-31 $28,745
2022-09-30 $28,482
2022-06-30 $28,684
2022-03-31 $30,586
2021-12-31 $30,690
2021-09-30 $22,907
2021-06-30 $24,033
2021-03-31 $24,002
2020-12-31 $25,360
2020-09-30 $26,321
2020-06-30 $26,156
2020-03-31 $21,637
2019-12-31 $22,736
2019-09-30 $22,677
2019-06-30 $22,771
2019-03-31 $22,721
2018-12-31 $19,806
2018-09-30 $19,936
2018-06-30 $19,959
2018-03-31 $21,501
2017-12-31 $21,353
2017-09-30 $21,838
2017-06-30 $21,706
2017-03-31 $23,437
2016-12-31 $24,274
2016-09-30 $23,656
2016-06-30 $23,642
2016-03-31 $23,656
2015-12-31 $23,829
2015-09-30 $24,124
2015-06-30 $24,069
2015-03-31 $25,506
2014-12-31 $18,699
2014-09-30 $18,566
2014-06-30 $18,590
2014-03-31 $19,589
2013-12-31 $20,539
2013-09-30 $22,647
2013-06-30 $22,526
2013-03-31 $16,089
2012-12-31 $16,254
2012-09-30 $17,571
2012-06-30 $15,057
2012-03-31 $15,228
2011-12-31 $15,525
2011-09-30 $15,692
2011-06-30 $15,783
2011-03-31 $15,644
2010-12-31 $15,482
2010-09-30 $14,032
2010-06-30 $13,835
2010-03-31 $15,281
2009-12-31 $16,095
2009-09-30 $8,205
2009-06-30 $8,181
2009-03-31 $3,939
2008-12-31 $3,943
2008-09-30 $3,939
2008-06-30 $3,932
2008-03-31 $3,965
2007-12-31 $3,916
2007-09-30 $3,874
2007-06-30 $4,134
2007-03-31 $5,545
2006-12-31 $5,551
2006-09-30 $4,790
2006-06-30 $4,759
2006-03-31 $4,763
2005-12-31 $5,126
2005-09-30 $5,125
2005-06-30 $5,672
2005-03-31 $5,656
2004-12-31 $4,692
2004-09-30 $4,394
2004-06-30 $4,894
2004-03-31 $4,932
2003-12-31 $5,096
2003-09-30 $5,399
2003-06-30 $5,394
2003-03-31 $5,376
2002-12-31 $4,879
2002-09-30 $4,870
2002-06-30 $4,834
2002-03-31 $4,790
2001-12-31 $4,799
2001-09-30 $4,235
2001-06-30 $3,656
2001-03-31 $3,623
2000-12-31 $3,601
2000-09-30 $3,438
2000-06-30 $3,439
2000-03-31 $3,443
1999-12-31 $3,144
1999-09-30 $3,214
1999-06-30 $3,213
1999-03-31 $3,218
1998-12-31 $3,221
1998-09-30 $2,726
1998-06-30 $1,344
1998-03-31 $1,845
1997-12-31 $1,347
1997-09-30 $1,690
1997-06-30 $1,727
1997-03-31 $1,232
1996-12-31 $1,156
1996-09-30 $1,328
1996-06-30 $1,506
1996-03-31 $1,516
1995-12-31 $1,373
1995-09-30 $1,337
1995-06-30 $916
1995-03-31 $1,168
1994-12-31 $1,146
1994-09-30 $1,104
1994-06-30 $1,017
1994-03-31 $1,093
1993-12-31 $1,121
1993-09-30 $577
1993-06-30 $578
1993-03-31 $489
1992-12-31 $496
1992-09-30 $600
1992-06-30 $596
1992-03-31 $582
1991-12-31 $494
1991-09-30 $590
1991-06-30 $538
1991-03-31 $121
1990-12-31 $124
1990-09-30 $125
1990-06-30 $124
1990-03-31 $118
1989-12-31 $118
1989-09-30 $102
1989-06-30 $102
1989-03-31 $103
1988-12-31 $143
1988-09-30 $278
1988-06-30 $298
1988-03-31 $167
1987-12-31 $167
1987-09-30 $168
1987-06-30 $168
1987-03-31 $169
1986-12-31 $168
1985-12-31 $171
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $270.018B $59.283B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12